TG Therapeutics Inc. (NASDAQ: TGTX) announced that its phase 3 ENHANCE trial met its primary endpoint, demonstrating bioequivalent drug exposure ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE